Fluoxetine HCl
Serotonin reuptake inhibitor / A selective serotonin reuptake inhibitor (SSRI) with high selectivity for the serotonin transporter (Kd=0.81 nM) over the norepinephrine (Kd=240 nM) and dopamine (Kd=3.6 uM) transporters.1 A clinically useful antidepressive agent.2 Has shown some potential in autism spectrum disorders.3 Attenuates neuroinflammation in early brain injury after subarachnoid hemorrhage.4 Orally active and active in vivo. Increases proliferation of neuronal precursors derived from human embryonic stem cells, inducing differentiation and strongly enhancing neuronal characteristics.5
Biochemicals & reagents
56296-78-7
LY-110,140
1) Tatsumi et al. (1997), Pharmacological profile of antidepressants and related compounds at human monoamine transporters; Eur. J. Pharmacol,, 340 249 2) Benfield et al. (1986), Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness; Drugs, 32 481 3) Benvenuto et al. (2013), Pharmacotherapy of autism spectrum disorders; Brain Dev., 35 119 4) Liu et al. (2018), Fluoxetine attenuates neuroinflammation in early brain injury after subarachnoid hemorrhage: a possible role for the regulation of TLR4/MyD88/NFkB signaling pathway; J. Neuroinflammation, 15 347 5) Chang et al. (2010), Increased cellular turnover in response to fluoxetine in neurona precursors derived from human embryonic stem cells; Prog. Int. J. Dev. Biol., 54 707
RT
TARGET: Monoamine transporter; Serotonin; Cytochrome/MDR -- PATHWAY: Proliferation -- RESEARCH AREA: Neuroscience; Stem cells -- DISEASE AREA: Inflammation; Mood disorders